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Abstract
Background
Currently ketogenic diets (KDs) are hyped as an anti-tumor intervention aimed at exploiting
the metabolic abnormalities of cancer cells. However, while data in humans is sparse, trans-
lation of murine tumor models to the clinic is further hampered by small sample sizes, het-
erogeneous settings and mixed results concerning tumor growth retardation. The aim was
therefore to synthesize the evidence for a growth inhibiting effect of KDs when used as a
monotherapy in mice.
Methods
We conducted a Bayesian random effects meta-analysis on all studies assessing the sur-
vival (defined as the time to reach a pre-defined endpoint such as tumor volume) of mice on
an unrestricted KD compared to a high carbohydrate standard diet (SD). For 12 studies
meeting the inclusion criteria either a mean survival time ratio (MR) or hazard ratio (HR)
between the KD and SD groups could be obtained. The posterior estimates for the MR and
HR averaged over four priors on the between-study heterogeneity τ2 were MR = 0.85 (95%
highest posterior density interval (HPDI) = [0.73, 0.97]) and HR = 0.55 (95% HPDI = [0.26,
0.87]), indicating a significant overall benefit of the KD in terms of prolonged mean survival
times and reduced hazard rate. All studies that used a brain tumor model also chose a late
starting point for the KD (at least one day after tumor initiation) which accounted for 26%
of the heterogeneity. In this subgroup the KD was less effective (MR = 0.89, 95% HPDI =
[0.76, 1.04]).
Conclusions
There was an overall tumor growth delaying effect of unrestricted KDs in mice. Future
experiments should aim at differentiating the effects of KD timing versus tumor location,
since external evidence is currently consistent with an influence of both of these factors.
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Introduction
While the first study assessing the effect of diet on cancer dates back to 1909 [1], there has
recently been a surge of attention regarding the metabolic hallmarks of cancer and the possibil-
ity to influence them through dietary manipulation. Dietary restriction, either of overall energy
consumption [1–4] or defined nutrients such as proteins [5,6] or carbohydrates [7,8], has
become the prime example of a dietary intervention influencing key pathways, growth and
metabolism of cancer. Such studies are difficult to perform in cancer patients, thus murine
tumor models have served as an essential tool to study the effect of dietary changes on these
pathways. In mice, dietary restriction has been shown to protect against the initiation of cancer
and to slow tumor growth after the manifestation of cancer [1,9]. Mechanistically, this has
been linked to decreased levels of glucose, insulin and insulin-like growth factors [10,11]. The
most potent anti-tumor effects have been described for fasting [12] which additionally leads to
a rapid increase in circulating ketone bodies in both men [13] and mice [14]. Ketogenic diets
(KDs), on the other hand, are fasting-mimicking diets that also lead to an increase in ketone
bodies without the need to restrict energy intake—a clear advantage in the cancer setting
[15,16]. A KD is typically composed of at least 75% fat with a maximum 10% of energy from
carbohydrate sources, corresponding to a ketogenic ratio of about 2:1. The ketogenic ratio is
defined as the weight percentage of fat in the diet divided by the combined weight percentage
of protein and carbohydrate [17].
KDs have shown anti-tumor potential in many, but not all mouse studies. The reason for
this discrepancy is not yet clear. In some studies, calorie restriction was required to elicit a
potent anti-tumor effect [18]. It has been argued that a lack of decreasing blood glucose levels
with ad libitum feeding would explain the lack of efficiency without caloric restriction. Indeed,
most murine tumor models report no significant decreases in blood glucose levels, and while
some studies do reveal a decrease [19–21], others report lower insulin levels compared to con-
trols despite unchanged or even elevated glucose levels [22,23].
In addition, a collective interpretation of murine tumor models is hampered by the large
variety of experiment setups and the small number of animals used in most studies. Thus there
remains some uncertainty concerning the anti-tumor effects of a KD in current preclinical
models. We therefore conducted a systematic review of the literature to ascertain the effects of
a KD on tumor growth, and to determine possible factors that may account for heterogeneity
in response to the KD.
Materials and Methods
Selection criteria
The inclusion criteria for this meta-analysis were defined a priori as follows:
1. Studies investigating tumor growth in a murine cancer model.
2. Studies testing the effects of an unrestricted KD with a ketogenic ratio of at least 2:1 on
tumor growth in comparison to a control standard diet (SD) with at least 50% energy con-
tent from CHO without additional treatment.
3. Endpoint defined as reaching a pre-defined tumor volume or other sign of disease progres-
sion with no termination of the experiment at a pre-defined time interval.
4. Conduction of a survival analysis with the specified endpoint, so that in principle either a
hazard ratio (HR) or a mean survival time ratio (MR) between the KD and the control diet
groups could be calculated.
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Studies not fulfilling all of the above four inclusion criteria were excluded from the analysis.
No registered protocol existed for this study.
Search strategy
Potentially relevant studies were searched January 5, 2016 in the PubMed database using the
search terms “ketogenic diet” AND “cancer”. References of selected articles and review articles
on this subject were searched for additional studies.
Data extraction
Data from each study and risk of bias were extracted independently by two authors (RJK and
CEC) using a preset form. In case of discrepancies between extracted data, consent was found
by discussion between these two reviewers. For each study, we recorded the year it was pub-
lished, the first author’s name, the tumor model used, the number of animals in each diet
group, the time when the diet intervention was started (prior to/at the same day of/after
tumor implantation), the ketogenic ratio of the chow and whether body weight under the KD
increased, decreased, or remained unchanged compared to the control regimen (Table 1).
Since the time points at which ketone body or glucose levels were evaluated in each study dif-
fered substantially, we decided to simply record whether there was a statistically significant dif-
ference (p<0.05) in these blood parameters at least once during the intervention. Furthermore,
the principle outcome measures MR and HR were extracted. Both were defined such that ratios
less than one indicated a beneficial effect of the KD. The HR is equivalent to the odds of dying
first and thus related to the probability P that a mouse from the KD group dies before a mouse
from the control group according to P = HR/(1+HR) [24]. 95% confidence intervals (CIs) for
the HR and standard errors (SE) of the mean survival times were also extracted; from the latter
95% CIs for the MR were derived.
If no mean survival times or uncertainty estimates were provided in the article, the corre-
sponding study author was contacted by one of us (RJK) to obtain this information. One study
[20] only reported a p-value based on a t-test comparison of the mean survival times. Although
this assumes that the individual survival times are normally distributed (which is usually not
the case and questionable even without censoring as in this study), we stayed consistent with
this assumption and used this p-value to estimate a SE for the mean survival time differences
according to the guidelines of Altman & Bland [25]; finally this SE was divided by
ﬃﬃﬃ
2
p
to obtain
the SE of the individual mean survival times in both groups under the assumption that they
would be equal.
Risk of bias was assessed by using the Systematic Review Centre for Laboratory animal
Experimentation (SYRCLE) tool which consists of 10 items for which judged based on a num-
ber of signaling questions [26]. It was decided to test the sensitivity of the results to withholding
studies with high risk of bias.
Finally, one of us (UK) extracted approximate blood concentrations of ketone bodies and
glucose from figures and data, which was possible for 10 studies. As crude estimates, these were
treated with care and only used to get an idea of the range of ketosis and blood glucose levels in
the mice.
Statistical analysis
We conducted a Bayesian meta-analysis. Compared to the classical approach this has several
advantages such as obtaining direct probability distributions for the parameters of interest, nat-
urally accounting for the full uncertainty in the parameters and allowing each individual study
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Table 1. Studies fulfilling all inclusion criteria for this meta-analysis: General data.
Publication
year
Study Tumor
model
Model details Location NKD+NSD Diet
initiation
Ketogenic
ratio
Ketosis Glycemia Body
weight
Comment
2007 Zhou S CT-2A brain tumor i.c.,
C57BL/6J mice
Brain 9+7 after 4:1 + 0 0 This study had two
separate experiments.
High risk of reporting
bias (no HR/MR given).
X U87 glioma s.c.,
C57BL/6J mice
Brain 7+11 after 4:1 + 0 0
2008 Freedland X LNCaP prostate s.c. s.c. 25+25 prior 2.1:1 + + 0 SD deﬁned as the
Western diet. KD mice
heavier than controls at
tumor implantation, but
this was accounted for
in HR computation.
2008 Otto X 23132/87 gastric
cancer s.c., NMRI mice
s.c. 12+12 day 0 2.7:1 + 0 0 High risk of selection,
performance and other
bias (KD mice lighter
than controls at tumor
implantation; individual
who performed the
experiments also
analyzed the data;
conﬂicts of interest).
2009 Mavropoulos X LAPC-4 prostate s.c.,
SCID mice
s.c. 48+41 prior 2.1:1 + 0 0 SD deﬁned as the
Western diet. High risk
of selection bias (KD
mice heavier than
controls at tumor
implantation).
2010 Stafford S GL261 glioma i.c.,
C57BL/6 mice
Brain 5+5 after 6:1 + NA NA High risk of reporting
bias (no body weight
trends reported)
2011 Maurer X LNT-229 glioma i.c.,
athymic Foxn1nu mice
Brain 12+12 after 2.7:1 + 0 0 High risk of reporting
bias (no HR/MR given).
Four mice in the SD
group and two in the
KD group were
censored and not
considered for mean
survival time
computation
2012 Abdelwahab S GL261 glioma i.c.,
C57BL/6 mice
Brain 20+19 after 4:1 + - 0 One mouse in the KD
group was cured and
not considered for
mean survival time
computation. High risk
of performance bias
(individual who
performed the
experiments also
analyzed the data;
conﬂicts of interest).
2013 Poff S VM-M3 metastatic
cancer, s.c., VM/Dk
mice
s.c. 8+13 day 0 4:1 0 - - Ketone bodies on KD
elevated, but not
signiﬁcantly. High risk
of performance bias
(individual who
performed the
experiments also
analyzed the data).
(Continued)
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“borrowing strength”, i.e., utilizing information from all other studies for estimating the “true”
study treatment effect [27,28]. To compare the effects of a KD with a SD, the MR was defined
as the primary and the HR as the secondary outcome of interest. The MR is typically more
appropriate than the HR for these type of studies in which the specified endpoint is eventually
reached by all animals [24]. All ratios were transformed to the natural logarithmic scale prior
to analysis.
We anticipated different, yet similar, effects of the KD intervention between the studies, so
that a random effects model was used [28]. A normal likelihood for the individual study obser-
vations was assumed [27–29]:
yi  Nðyi; s2i Þ ð1Þ
Here yi and si denote the outcome [ln(MR) or ln(HR)] and its SE in the ith study, and the
true study effects θi are assumed to be exchangeable [28] and drawn from an underlying distri-
bution given by
yi  Nðm; t2Þ ð2Þ
Table 1. (Continued)
Publication
year
Study Tumor
model
Model details Location NKD+NSD Diet
initiation
Ketogenic
ratio
Ketosis Glycemia Body
weight
Comment
2014 Rieger X U87MG glioma cells i.
c., athymic Foxn1nu
mice
Brain 8+8 after 3.1:1 + 0 0 High risk of reporting
and other bias (no HR/
MR given; conﬂicts of
interest).
2015 Hao X HCT116 colorectal s.c.,
BALBc/J SCID male
s.c. 24+12 day 0 3:1 + 0 0 Two KDs used (MKD
and LKD); both groups
pooled together.
2015 Dang S Spontaneous murine
medulloblastoma,
genetically engineered
Ptch1+/- Trp53-/- mice
on C57Bl/6:129SV
0background
Brain 4+4 after 4:1 + NA + High risk of reporting,
performance and other
forms of bias (no HR/
MR given; individual
who conducted the
experiment also
analyzed the data; no
ketone body
measurements
reported).
2015 Martuscello X Patient-derived L0
glioblastoma cells i.c.,
NOD/SCID mice
Brain 10+11 after 6:1 + - - Two ketogenic diets
used (KD and sHFLC)
but only KD considered
due to its high
ketogenic ratio. High
risk of selection,
reporting and other
forms of bias (time
from tumor
implantation until KD
initiation differed by up
to 4 days; no HR/MR
given).
Diet initiation refers to “day 0” which is the day of tumor implantation. S: syngeneic; X: xenogeneic. Ketosis and glycemia are coded such that 0 indicates
that no statistically signiﬁcant differences between both groups were found at any measurement (p>0.05), while the + and - signs indicate that there was
at least one measurement in which ketosis or blood glucose levels in the treatment group were signiﬁcantly higher (+) or lower (-), respectively, compared
to the control mice.
doi:10.1371/journal.pone.0155050.t001
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Heterogeneity was assessed by the between study variance τ2 which was modeled using four
different prior distributions [27,29]: (i) a prior for τ uniform on [0,2]; (ii) a half-normal prior
for τ with standard deviation 0.25, corresponding to an anticipated “upper” value for τ of 0.49;
(iii) a Gamma(0.001,0.001) prior on 1/τ2, which is close to being uniform on log(τ); (iv)
DuMouchel’s prior PðtÞ ¼ s0ðs0þtÞ2 with s
2
0 ¼ K=ð
PK
i¼1 s
2
i Þ being the harmonic mean of the K
individual study variances s2i . Using four different priors for τ probes the sensitivity of the
results to different a priori assumptions about the between-study heterogeneity.
Finally, Bayesian meta-regression [27,29] was conducted to determine the source of hetero-
geneity. Due to the small number of studies only univariate analysis was conducted:
yi  Nðmþ bxi; t2Þ ð3Þ
Here, xi is the covariate (also called moderator) for study i and β its regression coefficient.
Because ketosis, blood glucose and body weight trends were too uniform across the studies, we
decided to investigate the impact of the publication year, the tumor model (syngeneic/xenoge-
neic), the tumor location (intracranial/subcutaneous), the ketogenic ratio of the KD and time
of diet initiation as moderators of the MR and HR in subgroup analysis.
All analysis was conducted with R version 3.1.3 with the BRugs package and OpenBugs ver-
sion 3.2.2. Two Markov chains were individually initialized and the first 10000 Markov chain
Monte Carlo samples discarded. For the next 25000 iterations every fifth sample was kept to
obtain the posterior parameter distribution for the parameters of interest. The median was
taken as the parameter estimate and parameters considered “significant” when their 95% high-
est posterior density interval (HPDI) excluded zero.
Results
The PubMed search for “ketogenic diet” AND “cancer” resulted in a total of 72 articles of
which 23 were studies investigating the effects of a KD on tumor growth in a mouse model (Fig
1). From these 23 studies, seven were excluded because they conducted no survival analysis
[30–36], three were excluded since they terminated the experiments after a pre-defined time
interval [37–39] and one study was excluded because it had no control diet with>50% energy
from CHO [40]. Finally, we excluded the study of Poff et al. [41] published in 2015 since it was
essentially a replication of an earlier study of these authors with the same tumor model and
same mean survival time of the SD group. The remaining 11 studies fulfilled all inclusion crite-
ria and were considered for data extraction [7,18,20–23,42–46]. The study of Zhou et al. [18]
included two different tumor models which were evaluated separately. Two more studies fulfill-
ing the inclusion criteria were found by searching the references of review articles on this sub-
ject [19,47]. One of these two was a complementary mouse study to a clinical trial involving
glioblastoma patients [47]. An additional search for (“Low carbohydrate diet” OR “Atkins
diet”) AND “cancer” did not reveal any further studies fulfilling the inclusion criteria.
We were able to obtain sufficient data to compute either a MR or a HR from 12 of the 13
selected studies. The study supplying insufficient information was excluded (Fig 1). It used a
castrated prostate cancer xenograft model in which a significantly beneficial effect of a KD
compared to a Western-type diet was reported [7].
The general design and results of the included 12 studies is given in Table 1, while Table 2
provides results concerning the survival outcomes. Only two studies reported a HR [22,23]; for
six others we were able to retrieve the complete survival time data either from the authors
[19,42–44,47] or by reading them off the Kaplan-Meier plot [46], and computed HRs and 95%
CIs from the Cox proportional hazards model. From these complete datasets we also derived
mean survival times with their SE. Further mean survival times were either extracted directly
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from the studies [20,45] or provided by the study authors [18,21]. This resulted in a sample
of 11 studies (with 12 experiments) measuring a MR and 7 studies (8 experiments) measuring
a HR.
Not reporting MR and HR despite conducting a survival analysis was considered as evi-
dence for reporting bias. By retrieving these measures from the study authors we eliminated
the influence of this bias on the cumulative evidence. However, several other forms of bias
were identified in all but one study (Table 1), and not directly identified risk of bias was
mostly considered unclear since several aspects of methodology such as generation of the
Fig 1. Flow chart of the study selection procedure.
doi:10.1371/journal.pone.0155050.g001
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randomization sequence, allocation concealment or random outcome assessment [26] were
not reported. Overall, the risk of bias was judged as high but similar enough between studies to
not account for it in the analyses. An exception was possible bias due to financial conflicts of
interest reported by one or more study authors which we accounted for by conducting a sensi-
tivity analysis with the corresponding studies withheld.
When all studies were pooled together, a total of 192 mice were treated with a KD and 180
mice fed a SD. Mice receiving a KD had higher ketone body concentrations which was signifi-
cant in all studies but one [20] (mean concentrations extracted from 10 studies 1.6±0.4 mM
versus 0.3±0.1 mM). In most studies there were no significant differences in blood glucose lev-
els between both treatment groups, but on average concentrations on the KD tended to be
lower (7.0±1.0 mM versus 8.5±1.0 mM).
Eight of the 13 experiments found a significantly longer survival for mice receiving a KD
compared to a SD. The result of the meta-analysis for the overall effect of a KD on the MR and
HR is shown in Tables 3 and 4. The posterior estimates for the MR and HR averaged over all
four priors on τ2 were MR = 0.85 (95% HPDI = [0.73, 0.97]) and HR = 0.55 (95% HPDI =
[0.26, 0.87]). Thus there was a significant overall benefit of the KD in terms of prolonged mean
survival times and reduced odds of dying first. The effect measure estimates were not sensitive
to the type of prior used for the between-study variance. The estimate of τ2, however, was
highly sensitive to its prior in the meta-analysis when HR was used as the outcome. This proba-
bly reflects the greater uncertainty associated with the small number of studies. With MR as
the effect measure, estimates of τ2 were more uniform and reasonable, but the 95% HPDI sup-
ported both very small and substantial heterogeneity [29].
The overall protective effect was still apparent after excluding three studies with high risk
of bias due to financial conflicts of interest [19,42,47], but the 95% HPDI now included 1
(MR = 0.87, 95% HPDI = [0.70,1.04]). Also, excluding the study by Dang et al. [46] from which
we extracted the individual survival times out of the Kaplan-Meier plot did not change the
Table 2. Studies fulfilling all inclusion criteria for this meta-analysis: Outcome data.
Publication
year
Study TKD
[days]
TSD
[days]
MR MR 95%
CI
HR HR 95%
CI
Data source
2007 Zhou 19.7±0.9 16.7±1.4 0.85 [0.69,1.01] NA NA Mean survival times provided by author
18.7±0.9 22.5±1.8 1.20 [0.98,1.42] NA NA
2008 Freedland NA NA NA NA 0.48 [0.27,0.86] Publication
2008 Otto 34.2±2.5 23.3±1.1 0.68 [0.57,0.80] 0.16 [0.05,0.53] Individual survival times provided by author
2009 Mavropoulos NA NA NA NA 0.59 [0.37,0.93] Publication
2010 Stafford 24±1.1 19±0.7 0.79 [0.70,0.89] 0.07 [0.01,0.63] Individual survival times provided by author
2011 Maurer 82.4±1.2 94.9±1.3 1.15 [0.89,1.49] 1.65 [0.65,4.21] Individual survival times provided by author
2012 Abdelwahab 28.8±1.5 23.3±1.1 0.81 [0.70,0.92] 0.35 [0.17,0.71] Individual survival times provided by author
2013 Poff 48.9±4.4 31.2±4.4 0.64 [0.43,0.85] NA NA TKD and TSD taken from publication, standard errors
computed from p-value (see text for details)
2014 Rieger 35.6±0.7 33.9±1.6 0.95 [0.85,1.05] 0.79 [0.28,2.24] Individual survival times provided by author
2015 Hao 34.5
±10.1
24.8±3.1 0.72 [0.27,1.17] NA NA Publication
2015 Dang 17.8±0.5 16.3±2.3 0.92 [0.66,1.17] 1.43 [0.82,6.30] Publication; individual survival times read off Kaplan-
Meier plot
2015 Martuscello 56±4.2 38±1.0 0.68 [0.57,0.78] NA NA Mean survival times provided by author
TKD and TSD denote the mean survival times in the KD and SD groups, respective, and are given with their SE. These SE have been used to compute the
95% CI.
doi:10.1371/journal.pone.0155050.t002
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positive treatment effect estimate but slightly increased its uncertainty (MR = 0.84, 95% HPDI
= [0.70,1.01]).
Figs 2 and 3 show a forest plot for MR and HR, respectively, as the effect measure using the
inverse gamma prior on τ2. Note how the Bayesian estimates of the true study effects of each
trial are shifted towards the overall pooled effect and have decreased uncertainty by “borrowing
strength” from all the other trials.
There was a one-to-one correlation between time of diet initiation and tumor location, as all
experiments with intracranial tumors started the diet a few days after tumor manifestation and
vice versa. Accordingly, in meta-regression both the tumor location and the time at which the
KD was initiated were able to account for 26% of the heterogeneity between studies measuring
a MR. Brain tumors and the switch to the KD later than the day of tumor initiation were associ-
ated with less effectiveness of the KD with more than 90% probability (βlate diet initiation =
βbrain tumor = 0.29, 90% HPDI = [0.003, 0.54]). In this subgroup of studies the MR estimate was
0.89 (95% HPDI = [0.76, 1.04]), still supporting a positive effect, albeit no longer significantly.
The ketogenic ratio was able to explain only 1% of the heterogeneity between experiments
measuring a MR. An increase in the ketogenic ratio by 1 was thereby associated with a slight
decrease in the MR of -0.055 (95% HPDI = [-0.19, 0.08]), although only the 65% HPDI excluded
a zero effect (65% HPDI = [-0.11,-5.7×10−4]). For tumor model (syngeneic/xenogeneic) or year
of publication, no significant effects on the MR were found. None of the tested covariates were
Table 3. Results of the Bayesianmeta-analyses for the mean survival time ratio (MR) investigating four different priors for the between-study
variance.
Prior on τ Uniform prior Half-normal prior Inverse gamma prior DuMouchel prior
Overall effect exp(μ)
Prior distribution μ~N(0,100) μ~N(0,100) μ~N(0,100) μ~N(0,100)
Posterior median 0.85 0.85 0.85 0.85
Standard deviation 0.06 0.06 0.06 0.06
95% HPDI [0.72,0.98] [0.74,0.97] [0.73,0.97] [0.74,0.96]
Between-study variance τ2
Prior distribution τ~U(0,2) τ~HN(0,0.25) t2  Gð0:001; 0:001Þ PðtÞ ¼ s0ðs0þtÞ2
Posterior median 0.0388 0.0334 0.0315 0.0290
Standard deviation 0.0367 0.0266 0.0300 0.0260
95% HPDI [0.0106,0.1446] [0.0099,0.1078] [0.0086,0.1165] [0.0082,0.1022]
doi:10.1371/journal.pone.0155050.t003
Table 4. Similar to Table 3, but for the hazard ratio (HR) as the effect measure.
Prior on τ Uniform prior Half-normal prior Inverse gamma prior DuMouchel prior
Overall effect exp(μ)
Prior distribution μ~N(0,100) μ~N(0,100) μ~N(0,100) μ~N(0,100)
Posterior median 0.54 0.55 0.55 0.55
Standard deviation 0.20 0.11 0.17 0.16
95% HPDI [0.25,1.04] [0.38,0.80] [0.27,0.87] [0.30,0.92]
Between-study variance τ2
Prior distribution τ~U(0,2) τ~HN(0,0.25) t2  Gð0:001; 0:001Þ PðtÞ ¼ s0ðs0þtÞ2
Posterior median 0.49 0.0649 0.1914 0.1886
Standard deviation 0.7251 0.1111 0.658 0.5987
95% HPDI [0.0198,2.842] [0.0002,0.4019] [0.0012,2.076] [0.0004,1.822]
doi:10.1371/journal.pone.0155050.t004
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significantly correlated with a moderation of the overall HR, and accordingly no covariate was
able to explain part of the heterogeneity between studies assessing a HR.
Discussion
This meta-analysis indicates that in mice a KD prolongs survival (MR<1) and reduces the risk
of experiencing the pre-defined endpoint (HR<1) compared to a high-carbohydrate SD when
used as a monotherapy. It is therefore in line with a previous review by Lv et al. [9] in which
eight of the nine included mouse studies showed a protective effect against cancer, although no
systematic analysis of any outcome measure was conducted. We chose the MR as our primary
outcome, since in most KD studies all animals experienced the pre-defined endpoint, so that
the risk at the end of follow-up was not an issue [24].
The protective effect of the KD is most likely related to the state of ketosis, which was the
most consistent covariate across studies. In particular, survival seems to be less dependent on
weight loss in the KD group since most studies reported similar weight trends in both groups.
Amongst several putative effect moderators only the time of KD initiation or alternatively
tumor location were found to influence survival times and account for some of the between-
study heterogeneity, as all brain tumor models included in the analysis for MR were also the
ones using a late switch to the KD and vice versa. With more than 90% probability, the studies
Fig 2. Forest plot of the meta-analysis for the mean survival time ratio. Values less than 1 indicated a beneficial effect of the
KD. The observed effects Eq (1) are the effects extracted from the individual studies, while the Bayesian effect estimates Eq (2)
represent the true study effects and are influenced by all the other studies.
doi:10.1371/journal.pone.0155050.g002
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supported a survival-prolonging effect when the KD was started early (day of tumor cell injec-
tion) compared to at least one day after tumor cell injection or—alternatively—when a subcu-
taneous tumor instead of an intracranial one was used. Since it is currently not possible to
differentiate both effects based on the studies evaluated in this meta-analysis, other evidence
could be considered to reach a careful conclusion.
A protective role of the KD against early stages of tumorigenesis, but a much lesser effect
when tumor growth has already been initiated, would be consistent with results from the larg-
est rodent study on KD and cancer growth conducted to date. In this study, a total of 303 rats
were used to investigate the effects of a carbohydrate-free diet started either before or concur-
rently with tumor transplantation [48]. These experiments strongly implied that a carbohy-
drate-free diet started several weeks before tumor transplantation “. . .produces such an
influence upon the rats as to make them more resistant to tumor growth”, but also “. . .one is
left in no doubt on the ineffectiveness of non-carbohydrate feeding begun at the time of tumor
transplantation” [48]. Similarly, Moreschi’s seminal study from 1909 found a much stronger
tumor growth inhibiting or even preventing effect when mice received a calorically restricted
diet several days before rather than after tumor transplantation [1]. Finally, the meta-analysis
by Lv et al. [9] revealed a strong protective effect of preventive calorie restriction against tumor
incidence with a pooled odds ratio of 0.20 (95% CI [0.12,0.34]). Since the KD and calorie
restriction share similar metabolic effects, the interpretation that timing of the KD rather than
the tumor location matters would be consistent with these observations.
Fig 3. Forest plot of the meta-analysis for the hazard ratio. Values less than 1 indicated a beneficial effect of the KD.
doi:10.1371/journal.pone.0155050.g003
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On the other hand, Seyfried and coworkers have argued that unrestricted KDs are not effec-
tive against various brain tumor models [18], so the role of tumor location as a moderator of
survival times cannot be ruled out. Future studies should therefore assess the impact of an early
versus late switch to a KD in brain tumor and subcutaneous models to differentiate the influ-
ence of both covariates.
Translated into the clinic, our result would imply at best a weak effect of KDs as the sole
therapy against either already manifested tumors in general and/or brain tumors in particular.
It is interesting that both hypotheses are consistent with the findings from human studies on
glioblastoma multiforme, in which a KD as monotherapy seems ineffective in retarding tumor
growth but more promising when combined with standard treatments [49]. It is important
to stress that the experiments in which the switch to the KD occurred after tumor induction
reflect more the clinical situation in which patients adopt the KD as a supportive therapy after
being diagnosed with cancer. The situation of preventive timing of the KD may only apply to
secondary prevention—when patients try to influence their risk of recurrence of an eradicated
tumor. Therefore, in addition to testing the impact of tumor location and timing of the diet,
future studies in which a KD is started together with standard cancer treatment are important
as they probably have the greatest translational relevance. The results of the few such studies
published so far are indeed promising [19,38].
Our meta-analysis has several limitations. First, all animal studies assessing the KD have a
small sample size which leads to large uncertainties on the outcome measure. While this meta-
analysis can therefore help to reach an overall conclusion with better precision, one must pro-
vide caution with definitive conclusions, especially as other non-random biases not accounted
for can exist. Secondly, as expected, there was a moderate to large amount of heterogeneity
present. Although tumor location and/or the time of KD initiation were able to account for
roughly a quarter of this heterogeneity between studies using MR as the effect measure, much
of it remains unexplained and probably relates to the large variety of mouse strains, tumor cell
lines and endpoint criteria used. However, regardless the source of heterogeneity the results
were highly robust against various a priori assumptions about the heterogeneity. Thirdly, the
results might be sensitive to the various amounts of bias identified but also unidentified due to
underreporting. We have shown that removing three studies with financial conflicts of interest
still gave an overall protective effect of the KD, yet this was no longer significant. Thus we
judge the uncertainties of the overall result as higher than estimated due to various forms of
bias. Fourthly, the relations between individual blood glucose and ketone body levels on sur-
vival remain elusive. There is evidence for the importance of minimizing the ratio of glucose-
to-ketone body concentrations for brain tumor control, which would indicate that additional
calorie restriction could make KDs even more efficient [50]. However, there was insufficient
reporting of these quantities in the text of the reviewed studies providing a form of attrition
bias and showing a clear need for more detailed reporting of such important covariates
together with outcome statistics in future rodent studies. Furthermore, even if the mean values
would have been exactly known, regressing on mean values of animal characteristics would be
prone to the so-called aggregation bias which occurs when the relation between study mean
values and outcomes do not reflect the relation between individual values and individual out-
comes [27]. Our best efforts to obtain crude estimates from the graphs provided in each study
indicated that KD mice had on average blood glucose and ketone body concentrations around
7.0 mM and 1.6 mM, respectively, compared to 8.5 mM and 0.3 mM in the SD groups. While
this range of ketosis is also realistic for humans on a KD, the high blood glucose levels would
more reflect those of diabetic humans. Although many cancer patients also exhibit signs of
insulin resistance, the translational relevance of this remains unclear. It points out a general
limitation of mouse feeding studies since the metabolic response of mice to a certain diet can
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be age-, sex- and strain-dependent and very different from that of humans [51,52]. For exam-
ple, contrary to humans, the widely used C57Bl/6 mice exhibit large metabolic disturbances
when placed on a ketogenic diet if protein is not concurrently drastically restricted [51]. Having
a 7–8 times higher basal metabolic rate than humans, mice are also much more sensitive to
calorie restriction and intermittent fasting [53], so that any inter-study differences in feeding
behavior caused by, e.g., different housing conditions or dietary constituents causing different
grades of satiety, could additionally influence the outcome despite ad libitum food provision in
all studies.
Finally we note that several of the identified biases and other aspects of the tumor models
provide caution when extrapolating the results to humans. For instance, in some studies,
tumor cells are injected subcutaneously in the mouse prior to assessment of growth, as opposed
to their native organ location [22,23,42,45]. In these cases, large tumor sizes relative to the
mouse can be reached that in our experience (CO and UK) are no longer responsive to the KD.
Thus the KD must be started early to be effective. This may further hint to a benefit of the KD
to delay or inhibit tumor initiation, or in these studies, tumor implantation, if not started too
late. Of note, two studies that implanted syngeneic glioma cells into the brain revealed a benefit
from the KD [19,43].
In conclusion, we found that the published data thus far indicate that a KD impedes tumor
growth in mice. Our analysis reveals that the primary moderators of this effect may be the
tumor location (brain/subcutaneous) and time of diet initiation. However, the strong correla-
tion between these two covariates in the studies makes the exact mechanism elusive. Further-
more, all studies suffered from various biases and underreporting of methods whose influence
on our result also remains elusive. Future studies should therefore improve methodological
reporting and evaluate the effects of early versus late KD initiation for both subcutaneous and
intracranial tumors. Also the translationally most relevant setting of a KD initiation concurrent
with standard therapies after cancer manifestation should be more frequently investigated. If
the timing of the KD is of major importance this would imply a role of fasting and KDs as a
prevention strategy in humans, but only a supportive role during cancer treatment which is
consistent with the current available human data. Further studies in humans to test these
hypotheses are warranted.
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